Lacosamide Amarox (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyper‑excitable neurons, reduces repetitive firing, and helps prevent the spread of seizure activity.

The dosing regimen for Lacosamide Amarox is determined by the prescribing clinician based on the individual patient's clinical condition, renal function, and response to therapy. No fixed dose is provided here.

The safety of Lacosamide Amarox during pregnancy and lactation has not been definitively established. Clinicians should assess the potential benefits against possible risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Lacosamide differs from many traditional antiepileptics such as carbamazepine by selectively enhancing slow sodium‑channel inactivation, which may result in a distinct side‑effect profile and fewer drug‑interaction concerns. Compared with levetiracetam, it offers an alternative mechanism that can be useful in patients who have not responded to other agents.

Lacosamide Amarox should be stored at ambient temperature, below 25 °C, in its original container. Protect the solution from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

The product is supplied as an intravenous solution and is administered by slow infusion under medical supervision. The infusion rate and duration are set by the treating physician according to the patient’s therapeutic needs.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation or atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions, and emergence of suicidal thoughts. Prompt medical evaluation is required if any of these occur.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid its use. Individuals with significant cardiac conduction disorders (e.g., existing AV block) should be evaluated carefully before initiation.